LOH 19q indicates shorter disease progression-free interval in low-grade oligodendrogliomas with EMP3 methylation

Pasini,Alice; Iorio,Paolo; Bianchi,Emanuela; Cerasoli,Serenella; Cremonini,Anna   M.; Faedi,Marina; Guarnieri,Carlo; Guiducci,Graziano; Riccioni,Luca; Molinari,Chiara; Rengucci,Claudia; Calistri,Daniele; Giordano,Emanuele

doi:10.3892/or.2012.2047

LOH 19q indicates shorter disease progression-free interval in low-grade oligodendrogliomas with EMP3 methylation

Authors:
- Alice Pasini
- Paolo Iorio
- Emanuela Bianchi
- Serenella Cerasoli
- Anna M. Cremonini
- Marina Faedi
- Carlo Guarnieri
- Graziano Guiducci
- Luca Riccioni
- Chiara Molinari
- Claudia Rengucci
- Daniele Calistri
- Emanuele Giordano
View Affiliations

Affiliations: Laboratory of Cellular and Molecular Engineering ‘S. Cavalcanti’, University of Bologna, Cesena, Italy, Gruppo Neuroncologico Romagnolo (GNR), Cesena, Italy, Department of Biochemistry ‘G. Moruzzi’, University of Bologna, Bologna, Italy, IRCCS Romagnolo Scientific Institute for the Study and Treatment of Cancer (IRST), Meldola, Italy
Published online on: September 20, 2012 https://doi.org/10.3892/or.2012.2047
Pages: 2271-2277

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

We previously described a cohort of grade II oligodendroglioma (OII) patients, in whom the loss of heterozygosity (LOH) 19q was present in the subgroup at a higher risk of relapse. In this study, we evaluated the CpG methylation of the putative tumor suppressor epithelial membrane protein 3 (EMP3, 19q13.3) gene promoter in the same OII cohort, to investigate whether a correlation could be found between EMP3 cytogenetic and epigenetic loss and higher risk of relapse. Twenty-three tumor samples from OII patients were collected over a period of 10 years. Seventeen glioblastoma (GBM) samples (2 of which were relapses) were collected from 15 patients. The EMP3, O6-methylguanine methyltransferase (MGMT) and cyclooxygenase 2 (COX2) promoter methylation, evaluated by methylation-specific PCR, and the isocitrate dehydrogenase 1 (IDH1) mutation, identified by sequencing, were compared between the OII and GBM histotypes. The EMP3 promoter methylation was correlated with the analysis of LOH 19q, performed by microsatellite amplification, in OII patients. Disease progression-free interval was evaluated in the OII patients with the EMP3 methylation with either LOH 19q or conserved chromosome 19 arms. The EMP3 and MGMT promoter methylation was more frequent in OII than in GBM patients, and the IDH1 mutation was absent in GBM. The COX2 promoter was unmethylated in both histotypes. Both LOH+/- 19q OII patients showed EMP3 hypermethylation. Concomitant LOH 19q and EMP3 gene promoter methylation was observed in the OII patients at a higher risk of relapse. Our results suggest that a total (cytogenetic and epigenetic) functional loss of both EMP3 alleles accounts for the reduced disease progression-free interval in OII patients. Although the small sample size limits the strength of this study, our results support testing this hypothesis in larger cohorts of patients, considering the methylation of the EMP3 gene promoter together with LOH 19q as an indication for treatment with adjuvant therapy ab initio in order to improve the overall survival of OII patients.

View Figures

View References

1	Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al: The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 114:97–109. 2007. View Article : Google Scholar : PubMed/NCBI
2	El-Hateer H, Souhami L, Roberge D, Maestro RD, Leblanc R, Eldebawy, et al: Low-grade oligodendroglioma: an indolent but incurable disease? J Neurosurg. 111:265–271. 2009. View Article : Google Scholar : PubMed/NCBI
3	Mason WP: Oligodendroglioma. Curr Treat Options Neurol. 7:305–314. 2005. View Article : Google Scholar : PubMed/NCBI
4	Shaw EG, Berkey B, Coons SW, Bullard D, Brachman D, Buckner JC, et al: Recurrence following neurosurgeon-determined gross-total resection of adult supratentorial low-grade glioma: results of a prospective clinical trial. J Neurosurg. 109:835–841. 2008. View Article : Google Scholar
5	Pignatti F, van den Bent M, Curran D, Debruyne C, Sylvester R, Therasse P, Afra D, Cornu P, Bolla M, Vecht C and Karim AB; European Organization for Research and Treatment of Cancer Brain Tumor Cooperative Group; European Organization for Research and Treatment of Cancer Radiotherapy Cooperative Group. Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol. 20:2076–2084. 2002. View Article : Google Scholar : PubMed/NCBI
6	Jenkins RB, Blair H, Ballman KV, Giannini C, Arusell RM, Law M, et al: At(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res. 66:9852–9861. 2006. View Article : Google Scholar : PubMed/NCBI
7	Felsberg J, Erkwoh A, Sabel MC, Kirsch L, Fimmers R, Blaschke B, et al: Oligodendroglial tumours: refinement of candidate regions on chromosome arm 1p and correlation of 1p/19q status with survival. Brain Pathol. 14:121–130. 2004. View Article : Google Scholar : PubMed/NCBI
8	Okamoto Y, Di Patre PL, Burkhard C, Horstmann S, Jourde B, Fahey M, et al: Population-based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas. Acta Neuropathol. 108:49–56. 2004. View Article : Google Scholar
9	van den Bent MJ, Looijenga LH, Langenberg K, Dinjens W, Graveland W, Uytdewilligen L, et al: Chromosomal anomalies in oligodendroglial tumours are correlated with clinical features. Cancer. 97:1276–1284. 2003.PubMed/NCBI
10	Natsume A, Kondo Y, Ito M, Motomura K, Wakabayashi T and Yoshida J: Epigenetic aberrations and therapeutic implications in gliomas. Cancer Sci. 101:1331–1336. 2010. View Article : Google Scholar : PubMed/NCBI
11	Esteller M, Hamilton SR, Burger PC, Baylin SB and Herman JG: Inactivation of the DNA repair gene O⁶-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res. 59:793–797. 1999.PubMed/NCBI
12	Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V, et al: Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med. 343:1350–1354. 2000. View Article : Google Scholar
13	Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, et al: MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 352:997–1003. 2005. View Article : Google Scholar : PubMed/NCBI
14	Alaminos M, Dávalos V, Ropero S, Setién F, Paz MF, Herranz M, et al: EMP3, a myelin-related gene located in the critical 19q13.3 region, is epigenetically silenced and exhibits features of a candidate tumour suppressor in glioma and neuroblastoma. Cancer Res. 65:2565–2571. 2005. View Article : Google Scholar
15	Fumoto S, Tanimoto K, Hiyama E, Noguchi T, Nishiyama M and Hiyama K: EMP3 as a candidate tumor suppressor gene for solid tumors. Expert Opin Ther Targets. 13:811–822. 2009. View Article : Google Scholar : PubMed/NCBI
16	Qu M, Jiao H, Zhao J, Ren ZP, Smits A, Kere J and Nistér M: Molecular genetic and epigenetic analysis of NCX2/SLC8A2 at 19q13.3 in human gliomas. Neuropathol Appl Neurobiol. 36:198–210. 2010. View Article : Google Scholar : PubMed/NCBI
17	Taylor V and Suter U: Epithelial membrane protein-2 and epithelial membrane protein-3: two novel members of the peripheral myelin protein 22 gene family. Gene. 175:115–120. 1996. View Article : Google Scholar : PubMed/NCBI
18	Tews B, Felsberg J, Hartmann C, Kunitz A, Hahn M, Toedt G, et al: Identification of novel oligodendroglioma-associated candidate tumour suppressor genes in 1p36 and 19q13 using microarray-based expression profiling. Int J Cancer. 119:792–800. 2006. View Article : Google Scholar
19	Yim JH, Kim YJ, Ko JH, Cho YE, Kim SM, Kim JY, et al: The putative tumour suppressor gene GLTSCR2 induces PTEN-modulated cell death. Cell Death Differ. 14:1872–1879. 2007. View Article : Google Scholar : PubMed/NCBI
20	Li KK, Pang JC, Chung NY, Ng YL, Chan NH, Zhou L, et al: EMP3 overexpression is associated with oligodendroglial tumours retaining chromosome arms 1p and 19q. Int J Cancer. 120:947–950. 2007. View Article : Google Scholar : PubMed/NCBI
21	Kunitz A, Wolter M, van den Boom J, Felsberg J, Tews B, Hahn M, et al: DNA hypermethylation and aberrant expression of the EMP3 gene at 19q13.3 in human gliomas. Brain Pathol. 17:363–370. 2007. View Article : Google Scholar : PubMed/NCBI
22	Molinari C, Iorio P, Medri L, Ballardini M, Guiducci G, Cremonini AM, et al: Chromosome 1p and 19q evaluation in low-grade oligodendrogliomas: A descriptive study. Int J Mol Med. 25:145–151. 2010.PubMed/NCBI
23	Brandes AA, Tosoni A, Cavallo G, Reni M, Franceschi E, Bonaldi L, et al: Correlations between O⁶-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a prospective GICNO study. J Clin Oncol. 24:4746–4753. 2006.PubMed/NCBI
24	Ichimura K, Pearson DM, Kocialkowski S, Bäcklund LM, Chan R, Jones DT and Collins VP: IDH1 mutations are present in the majority of common adult gliomas but are rare in primary glioblastomas. Neuro Oncol. 11:341–347. 2009. View Article : Google Scholar : PubMed/NCBI
25	Herman JG, Graff JR, Myöhänen S, Nelkin BD and Baylin SB: Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA. 93:9821–9826. 1996. View Article : Google Scholar : PubMed/NCBI
26	Giannini C, Burger PC, Berkey BA, Cairncross JG, Jenkins RB, Mehta M, et al: Anaplastic oligodendroglial tumours: refining the correlation among histopathology, 1p 19q deletion and clinical outcome in Intergroup Radiation Therapy Oncology Group Trial 9402. Brain Pathol. 18:360–369. 2008. View Article : Google Scholar
27	Bello MJ, Leone PE, Vaquero J, de Campos JM, Kusak ME, Sarasa JL, et al: Allelic loss at 1p and 19q frequently occurs in association and may represent early oncogenic events in oligodendroglial tumours. Int J Cancer. 64:207–210. 1995. View Article : Google Scholar : PubMed/NCBI
28	Smith JS, Alderete B, Minn Y, Borell TJ, Perry A, Mohapatra G, et al: Localization of common deletion regions on 1p and 19q in human gliomas and their association with histological subtype. Oncogene. 18:4144–4152. 1999. View Article : Google Scholar : PubMed/NCBI
29	Kaneshiro D, Kobayashi T, Chao ST, Suh J and Prayson RA: Chromosome 1p and 19q deletions in glioblastoma multiforme. Appl Immunohistochem Mol Morphol. 17:512–516. 2009. View Article : Google Scholar : PubMed/NCBI
30	Nigro JM, Misra A, Zhang L, Smirnov I, Colman H, Griffin C, et al: Integrated array-comparative genomic hybridization and expression array profiles identify clinically relevant molecular subtypes of glioblastoma. Cancer Res. 65:1678–1686. 2005. View Article : Google Scholar
31	Ruano Y, Mollejo M, Ribalta T, Fiaño C, Camacho FI, Gómez E, et al: Identification of novel candidate target genes in amplicons of Glioblastoma multiforme tumors detected by expression and CGH microarray profiling. Mol Cancer. 5:392006. View Article : Google Scholar : PubMed/NCBI
32	Fumoto S, Hiyama K, Tanimoto K, Noguchi T, Hihara J, Hiyama E, et al: EMP3 as a tumor suppressor gene for esophageal squamous cell carcinoma. Cancer Lett. 274:25–32. 2009. View Article : Google Scholar : PubMed/NCBI